Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Culture Media | 2 | 2019 | 366 | 0.83 | Why? |
| Microbiological Techniques | 2 | 2019 | 232 | 0.83 | Why? |
| Cystic Fibrosis | 2 | 2020 | 1104 | 0.76 | Why? |
| Hepatitis A | 2 | 2018 | 140 | 0.76 | Why? |
| Bacteriological Techniques | 2 | 2019 | 239 | 0.73 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2020 | 214 | 0.70 | Why? |
| Hepatitis A Vaccines | 1 | 2018 | 52 | 0.70 | Why? |
| Evaluation Studies as Topic | 1 | 2019 | 391 | 0.68 | Why? |
| Azabicyclo Compounds | 1 | 2018 | 91 | 0.67 | Why? |
| Microbiology | 1 | 2019 | 134 | 0.66 | Why? |
| Ceftazidime | 1 | 2018 | 134 | 0.65 | Why? |
| Environmental Pollution | 1 | 2019 | 344 | 0.58 | Why? |
| Enterobacteriaceae Infections | 1 | 2020 | 529 | 0.55 | Why? |
| Homosexuality, Male | 3 | 2018 | 1158 | 0.55 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2021 | 846 | 0.53 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 449 | 0.51 | Why? |
| Clinical Laboratory Services | 1 | 2019 | 781 | 0.48 | Why? |
| Orthomyxoviridae | 1 | 2021 | 1168 | 0.47 | Why? |
| Mouth | 1 | 2017 | 622 | 0.47 | Why? |
| Streptococcus pneumoniae | 1 | 2017 | 827 | 0.46 | Why? |
| Equipment Contamination | 2 | 2019 | 1308 | 0.43 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.40 | Why? |
| Disinfection | 2 | 2020 | 2912 | 0.39 | Why? |
| Sexually Transmitted Diseases | 1 | 2017 | 694 | 0.39 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.37 | Why? |
| Lung Transplantation | 1 | 2020 | 1554 | 0.36 | Why? |
| Cross Infection | 3 | 2020 | 8675 | 0.36 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.35 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.34 | Why? |
| Nasopharynx | 3 | 2021 | 10224 | 0.34 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.33 | Why? |
| Laboratories | 1 | 2019 | 2858 | 0.31 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2020 | 13720 | 0.30 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.28 | Why? |
| Paris | 2 | 2018 | 1287 | 0.26 | Why? |
| France | 6 | 2020 | 12074 | 0.24 | Why? |
| Viral Nonstructural Proteins | 1 | 2020 | 4810 | 0.24 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.22 | Why? |
| Anti-Bacterial Agents | 4 | 2019 | 10083 | 0.21 | Why? |
| Incubators | 1 | 2019 | 3 | 0.21 | Why? |
| Proteoglycans | 1 | 2021 | 130 | 0.21 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.21 | Why? |
| Achromobacter | 1 | 2018 | 4 | 0.19 | Why? |
| Streptococcus | 1 | 2019 | 76 | 0.19 | Why? |
| Burkholderia cepacia complex | 1 | 2018 | 18 | 0.19 | Why? |
| Calibration | 1 | 2019 | 307 | 0.18 | Why? |
| Amoxicillin | 1 | 2019 | 98 | 0.18 | Why? |
| Nocardia Infections | 1 | 2018 | 37 | 0.18 | Why? |
| Stenotrophomonas maltophilia | 1 | 2018 | 63 | 0.18 | Why? |
| Platelet Factor 4 | 1 | 2021 | 385 | 0.17 | Why? |
| Quinine | 1 | 2017 | 56 | 0.17 | Why? |
| Pneumonia, Pneumocystis | 1 | 2021 | 322 | 0.16 | Why? |
| Neoplasm Proteins | 1 | 2021 | 501 | 0.15 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.15 | Why? |
| Sexually Transmitted Diseases, Viral | 1 | 2017 | 115 | 0.15 | Why? |
| Streptococcal Infections | 1 | 2019 | 255 | 0.15 | Why? |
| Fungi | 1 | 2019 | 471 | 0.15 | Why? |
| Hepatitis B Vaccines | 1 | 2017 | 245 | 0.15 | Why? |
| Microbial Sensitivity Tests | 3 | 2019 | 2886 | 0.14 | Why? |
| Quality Control | 1 | 2019 | 628 | 0.14 | Why? |
| HIV Infections | 2 | 2018 | 11620 | 0.14 | Why? |
| von Willebrand Factor | 1 | 2021 | 668 | 0.14 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.14 | Why? |
| Antibodies | 1 | 2021 | 846 | 0.14 | Why? |
| Disease Transmission, Infectious | 1 | 2018 | 9044 | 0.14 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.14 | Why? |
| Enterobacteriaceae | 1 | 2018 | 395 | 0.14 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.14 | Why? |
| Environmental Microbiology | 1 | 2019 | 575 | 0.13 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.13 | Why? |
| Endocarditis | 1 | 2019 | 368 | 0.13 | Why? |
| Klebsiella Infections | 1 | 2018 | 466 | 0.13 | Why? |
| Pseudomonas aeruginosa | 1 | 2018 | 652 | 0.13 | Why? |
| Klebsiella pneumoniae | 1 | 2018 | 658 | 0.12 | Why? |
| Humans | 26 | 2021 | 930598 | 0.12 | Why? |
| Opportunistic Infections | 1 | 2018 | 602 | 0.11 | Why? |
| Morbidity | 1 | 2017 | 1426 | 0.11 | Why? |
| Pneumococcal Infections | 1 | 2017 | 562 | 0.11 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.10 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.10 | Why? |
| Male | 16 | 2021 | 367725 | 0.10 | Why? |
| Clostridium Infections | 1 | 2016 | 595 | 0.09 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2018 | 1138 | 0.09 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.09 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.09 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.09 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Adult | 10 | 2021 | 244371 | 0.09 | Why? |
| Sexual and Gender Minorities | 1 | 2017 | 1019 | 0.08 | Why? |
| Aged | 11 | 2021 | 215776 | 0.08 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.07 | Why? |
| Evolution, Molecular | 1 | 2018 | 3691 | 0.07 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2016 | 2328 | 0.06 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| Algorithms | 2 | 2017 | 7346 | 0.06 | Why? |
| Female | 11 | 2021 | 380317 | 0.06 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.06 | Why? |
| ADAM Proteins | 1 | 2021 | 43 | 0.06 | Why? |
| Specimen Handling | 1 | 2019 | 6190 | 0.05 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.05 | Why? |
| Fimbriae, Bacterial | 1 | 2018 | 14 | 0.05 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.05 | Why? |
| Nocardia | 1 | 2018 | 21 | 0.05 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Pneumocystis carinii | 1 | 2021 | 205 | 0.05 | Why? |
| Colony Count, Microbial | 1 | 2018 | 177 | 0.04 | Why? |
| Fertilization in Vitro | 1 | 2021 | 330 | 0.04 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.04 | Why? |
| ADAMTS13 Protein | 1 | 2021 | 363 | 0.04 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.04 | Why? |
| Colistin | 1 | 2018 | 217 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.04 | Why? |
| Biofilms | 1 | 2018 | 304 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.04 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 877 | 0.03 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.03 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.03 | Why? |
| Propensity Score | 1 | 2020 | 2690 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.03 | Why? |
| Emergency Service, Hospital | 1 | 2016 | 14232 | 0.03 | Why? |
| Proton Pump Inhibitors | 1 | 2016 | 377 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Leukocyte Count | 1 | 2021 | 3178 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Blood Platelets | 1 | 2021 | 1704 | 0.03 | Why? |
| Bacterial Proteins | 1 | 2018 | 1318 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
| Fatal Outcome | 1 | 2018 | 3438 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| Endoscopy | 1 | 2018 | 1564 | 0.02 | Why? |
| Bacteremia | 1 | 2018 | 1372 | 0.02 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.02 | Why? |
| Patient Readmission | 1 | 2016 | 1543 | 0.02 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2021 | 7220 | 0.02 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Lung Diseases | 1 | 2018 | 2361 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2021 | 5486 | 0.02 | Why? |
| Diabetes Complications | 1 | 2016 | 2358 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.01 | Why? |
| Kidney Failure, Chronic | 1 | 2016 | 3222 | 0.01 | Why? |
| Hospitals | 1 | 2019 | 11793 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Risk Factors | 2 | 2019 | 71621 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |
Farfour's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(165)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(75)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_